drugset / Trial / NCT06030375
Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567
RandomizedSequentialDouble-blindTreatment
Summary
The study was planned to consist of 24 healthy subjects in 3 dosing cohorts receiving a continuous i.v. infusion of KAND567 or placebo for 6 h (6 subjects on active and 2 subjects on placebo per cohort), with the option of two additional cohorts of the same size and group composition.
Timeline
- Start
- 2020-02-17
- Primary completion
- 2020-04-27
- Completion
- 2020-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AZD-8797 | Small molecule | 33.8 mg | Intravenous |
| Comparator | AZD-8797 | Small molecule | 67 mg | Intravenous |
| Comparator | AZD-8797 | Small molecule | 134 mg | Intravenous |
Indications
No indication recorded.